Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression

Table 3 Association between clinicopathologic characteristics and CDC20 expression

Patient and tumor characteristic	N	CDC20 expression^h	P
Age (years)
< 60	17	8.93 ± 17.29	0.449^a
60-70	24	4.54 ± 6.68
> 70	15	5.32 ± 7.72
Lymph node metastasis
Present	39	6.54 ± 12.86	0.646^b
Absent	17	5.03 ± 5.78
Tumor size (cm)
≤2.0	10	2.98 ± 3.10	0.314^c
> 2.0	43	7.05 ± 12.50
Unknown	3	2.50 ± 3.38
Tumor differentiation
Well or moderate	41	4.01 ± 5.93	0.020^d
Poor	15	11.76 ± 18.48
Tumor stage
IA and IB	1	19.02 ± N/A
IIA	16	4.16 ± 4.66	0.482^e
IIB	37	6.56 ± 13.18
IV	2	6.15 ± N/A
Tumor margin
Negative	45	6.09 ± 11.72	0.993^f
Positive	11	6.06 ± 8.96
Tumor recurrence
None	12	4.76 ± 5.33	0.308^g
Local and regional	12	2.39 ± 1.97
Metastasis	32	7.96 ± 14.14

a. Age range, < 60 versus 60-70 versus > 70 (one-way ANOVA).
b. Lymph node metastasis, present versus absent (Student's t-test).
c. Tumor size, ≤ 2.0 cm versus > 2.0 cm (Student's t-test)
d. Differentiation grade, well or moderate versus poor (Student's t-test).
e. Tumor stage, IIA versus IIB (Student's t-test).
f. Tumor margin, negative versus positive (Student's t-test).
g. Tumor recurrence, no recurrence versus local and regional recurrence versus metastasis (one-way ANOVA).
h. The percentage of positive cells with CDC20 protein expression; Mean ± Standard deviation

ISSN: 1756-8722